We continue to see expansion of indications and technology in genetic engineering applied to human diseases. Gene editing and base editing methods have evolved quickly and moved into large-scale manufacturing and clinical trials. We also see new disease-specific and regulatory challenges. Insertion site analysis of integrating vectors in human trials is leading to new understanding of hematopoiesis and cancer immunology. As in the past, this meeting brings together international experts discussing state-of-the-art gene transfer and gene therapy clinical applications, new vector approaches and insertional genome biology. Meeting limited to 100 participants.

Sponsored by the Transatlantic Gene Therapy Consortium
Organizing Committee: Christopher Baum, Alessandra Biffi, Donald Kohn, Sung-Yun Pai, Matthew Porteus, Adrian Thrasher, Axel Schambach & David Williams